Search

About us

Welcome to the family! Get to know the Young EHA Committee and learn how you can make a difference. Join Young EHA through a junior membership. Meet the Young EHA committee members:

 
 
Name: Mandy N.

Read more

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Read more

Chronic Myeloid Leukemia

The objective of this SWG is the cure of Chronic Myeloid Leukemia (CML) by cooperative research.

Read more

EHA Guidelines on Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults

Chronic myelomonocytic leukemia (CMML) is a disease of the elderly, and by far the most frequent overlap myelodysplastic/myeloproliferative neoplasm in adults.

Read more

EHA and PTHiT Successfully Conclude the Second Joint Virtual Mini Hematology Tutorial

EHA-PTHiT Mini Hematology Tutorial

November 15-16, 2021

Meeting chairs:

Prof G Gaidano (European Hematology Association)
Prof I Hus (Polish Society of Hematology and Transfusion)
Prof T Robak (Polish Society of Hematology and Transfusion) 
After a successful mini Tutorial in April 2021, EHA and PTHiT decided to…

Read more

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…

Read more

Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis

111 hematologists from 31 countries met in Barcelona for a three-day scientific meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis.

Read more

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more